Health Care - As introduced, authorizes a patient with a severe chronic disease or terminal illness to access, and a physician to recommend, investigational stem cell treatment; requires the commissioner of health to promulgate rules to, among other things, list the medical conditions that constitute a qualifying severe chronic disease or terminal illness. - Amends TCA Title 53; Title 63 and Title 68.

SB 152 allows patients with severe chronic diseases or terminal illnesses to access investigational stem cell treatments (adult stem cell therapies still in clinical trials and not yet FDA-approved) after their doctors confirm other FDA-approved treatments aren't viable. It requires Tennessee’s health commissioner to create rules listing qualifying medical conditions and mandates doctors to document that all standard treatments were considered before recommending these experimental therapies. The bill also protects physicians from license penalties for following these guidelines and prohibits government interference with patient access. This directly affects patients with qualifying conditions and their treating physicians in Tennessee.